d1000 Varejo Farma Participacoes SA

The company’s capital structure shows a debt-to-equity ratio of 0.52, indicating moderate leverage, with long-term debt of BRL 475.0 million against total equity of BRL 919.3 million. Liquidity is constrained, with a current ratio of 1.08 and only BRL 40.1 million in cash and equivalents, which is insufficient to cover total liabilities of BRL 1.03 billion. Free cash flow of BRL 64.9 million is positive but limited in scale relative to the company’s debt obligations. Profitability metrics are weak, with a return on equity of 2.45% and return on assets of 1.16%, both below the typical thresholds for a profitable retail operation. Operating income of BRL 83.9 million and net income of BRL 22.6 million suggest thin margins, which may reflect competitive pricing pressures or high operating costs in the drug retail sector. Geographically, the company is concentrated in five Brazilian states, with no disclosed international presence or diversification beyond this regional footprint. Revenue of BRL 2.67 billion is entirely attributed to these domestic markets, which exposes the company to local economic and regulatory risks. Growth appears modest, with the most recent actual revenue of BRL 2.16 billion reported by analysts, compared to the BRL 2.67 billion in the latest financial snapshot. This suggests a recent increase in revenue, but the pace and sustainability of this growth are unclear without forward-looking guidance or segment-level performance data. Risk factors include liquidity constraints, as the company’s cash and equivalents are insufficient to cover its total debt, and a medium liquidity risk rating. Dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted metrics. However, the company’s net cash position is negative after subtracting total debt, which could necessitate future financing or asset sales. Recent events include the latest financial reporting period, which shows a net income of BRL 22.6 million and a capital expenditure of BRL 92.4 million. No recent filings or transcripts were provided in the input data, so no additional commentary on management guidance or strategic shifts is available.